Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Research & Development (2016 - 2025)

Assembly Biosciences has reported Research & Development over the past 11 years, most recently at $17.2 million for Q4 2025.

  • Quarterly results put Research & Development at $17.2 million for Q4 2025, up 20.8% from a year ago — trailing twelve months through Dec 2025 was $64.8 million (up 15.88% YoY), and the annual figure for FY2025 was $64.8 million, up 15.88%.
  • Research & Development for Q4 2025 was $17.2 million at Assembly Biosciences, up from $16.6 million in the prior quarter.
  • Over the last five years, Research & Development for ASMB hit a ceiling of $18.6 million in Q1 2021 and a floor of $10.8 million in Q3 2023.
  • Median Research & Development over the past 5 years was $16.2 million (2024), compared with a mean of $15.4 million.
  • Biggest five-year swings in Research & Development: plummeted 55.99% in 2021 and later increased 29.83% in 2024.
  • Assembly Biosciences' Research & Development stood at $14.7 million in 2021, then increased by 14.28% to $16.9 million in 2022, then tumbled by 34.69% to $11.0 million in 2023, then grew by 29.75% to $14.3 million in 2024, then grew by 20.8% to $17.2 million in 2025.
  • The last three reported values for Research & Development were $17.2 million (Q4 2025), $16.6 million (Q3 2025), and $16.1 million (Q2 2025) per Business Quant data.